Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Transcription factor NRF2 as a therapeutic target for chronic diseases: A systems medicine approach

  • Cuadrado, Antonio
  • Manda, Gina
  • Hassan, Ahmed
  • Alcaraz, María José
  • Barbas, Coral
  • Daiber, Andreas
  • Ghezzi, Pietro
  • León, Rafael
  • López, Manuela G.
  • Oliva Miguel, Baldomero
  • Pajares, Marta
  • Rojo, Ana I.
  • Robledinos Antón, Natalia
  • Valverde, Ángela María
  • Guney, Emre
  • Schmidt, Harald H.H.W.
Systems medicine has a mechanism-based rather than a symptom- or organ-based approach to disease and identifies therapeutic targets in a nonhypothesis-driven manner. In this work, we apply this to transcription factor nuclear factor (erythroid-derived 2)-like 2 (NRF2) by cross-validating its position in a protein-protein interaction network (the NRF2 interactome) functionally linked to cytoprotection in low-grade stress, chronic inflammation, metabolic alterations, and reactive oxygen species formation. Multiscale network analysis of these molecular profiles suggests alterations of NRF2 expression and activity as a common mechanism in a subnetwork of diseases (the NRF2 diseasome). This network joins apparently heterogeneous phenotypes such as autoimmune, respiratory, digestive, cardiovascular, metabolic, and neurodegenerative diseases, along with cancer. Importantly, this approach matches and confirms in silico several applications for NRF2-modulating drugs validated in vivo at different phases of clinical development. Pharmacologically, their profile is as diverse as electrophilic dimethyl fumarate, synthetic triterpenoids like bardoxolone methyl and sulforaphane, protein-protein or DNA-protein interaction inhibitors, and even registered drugs such as metformin and statins, which activate NRF2 and may be repurposed for indications within the NRF2 cluster of disease phenotypes. Thus, NRF2 represents one of the first targets fully embraced by classic and systems medicine approaches to facilitate both drug development and drug repurposing by focusing on a set of disease phenotypes that appear to be mechanistically linked. The resulting NRF2 drugome may therefore rapidly advance several surprising clinical options for this subset of chronic diseases., This work was supported by Grants SAF2015-71304-REDT, SAF2016-76520-R, SAF2013-4874R, SAF2015-65267-R, and BIO2014-57518 of the Spanish Ministry of Economy and Competiveness; PII4/00372 from the Health Institute Carlos III; PROMETEOII/2014/071 of Generalitat Valenciana; P_37_732/2016 REDBRAIN of the European Regional Development Fund; Competitiveness Operational Program 2014-2020; and the ERC Advanced Grant RadMed 294683 and COST action 15120 OpenMultiMed (H.H.H.W.S.). M.P. is the recipient of a FPU fellowship of Autonomous University of Madrid. E.G. is supported by a European-cofunded Beatriu de Pinos fellowship. R.L. is supproted by the Miguel Servet II fellow (CPII16/00014).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine Approach

  • Cuadrado, Antonio
  • Manda, Gina
  • Hassan, Ahmed
  • ALCARAZ TORMO, Mª JOSE
  • Barbas, Coral
  • Daiber, Andreas
  • Ghezzi, Pietro
  • León, Rafael
  • Lopez, Manuela G.
  • Oliva, Baldo
  • Pajares, Marta
  • Rojo, Ana I.
  • Robledinos-Antón, Natalia
  • Valverde, Ángela M.
  • Guney, Emre
This work was supported by Grants SAF2015-71304-REDT, SAF2016-76520-R, SAF2013-4874R, SAF2015-65267-R, and BIO2014-57518 of the Spanish Ministry of Economy and Competiveness; PII4/00372 from the Health Institute Carlos III; PROMETEOII/2014/071 of Generalitat Valenciana; P_37_732/2016 REDBRAIN of the European Regional Development Fund; Competitiveness Operational Program 2014-2020; and the ERC Advanced Grant RadMed 294683 and COST action 15120 OpenMultiMed (H.H.H.W.S.). M.P. is the recipient of a FPU fellowship of Autonomous University of Madrid. E.G. is supported by a European-cofunded Beatriu de Pinos fellowship. R.L. is supproted by the Miguel Servet II fellow (CPII16/00014)
Biblos-e Archivo. Repositorio Institucional de la UAM
Publication Artículo científico (JournalArticle)

On the Clinical Pharmacology of Reactive Oxygen Species

  • Casas, Ana I.
  • Nogales, Cristian
  • Mucke, Hermann A.M.
  • Petraina, Alexandra
  • Cuadrado Pastor, Antonio
  • Rojo Sanchís, Ana Isabel
  • Ghezzi, Pietro
  • Jaquet, Vincent
  • Augsburger, Fiona
  • Dufrasne, Francois
  • Soubhye, Jalal
  • Deshwal, Soni
  • Sante, Moises Di
  • Kaludercic, Nina
  • Lisa, Fabio Di
  • Schmidt, Harald H.H.W.
Reactive oxygen species (ROS) have been correlated with almost every human disease. Yet clinical exploitation of these hypotheses by pharmacological modulation of ROS has been scarce to nonexistent. Are ROS, thus, irrelevant for disease? No. One key misconception in the ROS field has been its consideration as a rather detrimental metabolic by-product of cell metabolism, and thus, any approach eliminating ROS to a certain tolerable level would be beneficial. We now know, instead, that ROS at every concentration, low or high, can serve many essential signaling and metabolic functions. This likely explains why systemic, nonspecific antioxidants have failed in the clinic, often with neutral and sometimes even detrimental outcomes. Recently, drug development has focused, instead, on identifying and selectively modulating ROS enzymatic sources that in a given constellation cause disease while leaving ROS physiologic signaling and metabolic functions intact. As sources, the family of NADPH oxidases stands out as the only enzyme family solely dedicated to ROS formation. Selectively targeting disease-relevant ROS-related proteins is already quite advanced, as evidenced by several phase II/III clinical trials and the first drugs having passed registration. The ROS field is expanding by including target enzymes and maturing to resemble more and more modern, big data–enhanced drug discovery and development, including network pharmacology. By defining a disease based on a distinct mechanism, in this case ROS dysregulation, and not by a symptom or phenotype anymore, ROS pharmacology is leaping forward from a clinical underperformer to a proof of concept within the new era of mechanism-based precision medicine, This study was supported by the European Research Council Advanced Investigator Grant/RadMed [Grant294683], Proof-of-Concept Grant/SAVEBRAIN[Grant737586] and H2020 Project REPO-TRIAL[Grant777111] (to H.H.H.W.S.) and short-term scientific mission sby the COST Actions EU-ROS and Open-MultiMed, and Kootstra Talented Fellowship (MaastrichtUniversity) (toA.I.C.)
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Transcription factor NRF2 as a therapeutic target for chronic diseases: A systems medicine approach

  • Cuadrado, Antonio
  • Manda, Gina
  • Hassan, Ahmed
  • Alcaraz, María José
  • Barbas, Coral
  • Daiber, Andreas
  • Ghezzi, Pietro
  • León, Rafael
  • López, Manuela G.
  • Oliva, Baldo
  • Pajares, Marta
  • Rojo, Ana I.
  • Robledinos-Antón, Natalia
  • Valverde, Ángela M.
  • Guney, Emre
  • Schmidt, Harald H.H.W.
Systems medicine has a mechanism-based rather than a symptom- or organ-based approach to disease and identifies therapeutic targets in a nonhypothesis-driven manner. In this work, we apply this to transcription factor nuclear factor (erythroid-derived 2)-like 2 (NRF2) by cross-validating its position in a protein-protein interaction network (the NRF2 interactome) functionally linked to cytoprotection in low-grade stress, chronic inflammation, metabolic alterations, and reactive oxygen species formation. Multiscale network analysis of these molecular profiles suggests alterations of NRF2 expression and activity as a common mechanism in a subnetwork of diseases (the NRF2 diseasome). This network joins apparently heterogeneous phenotypes such as autoimmune, respiratory, digestive, cardiovascular, metabolic, and neurodegenerative diseases, along with cancer. Importantly, this approach matches and confirms in silico several applications for NRF2-modulating drugs validated in vivo at different phases of clinical development. Pharmacologically, their profile is as diverse as electrophilic dimethyl fumarate, synthetic triterpenoids like bardoxolone methyl and sulforaphane, protein-protein or DNA-protein interaction inhibitors, and even registered drugs such as metformin and statins, which activate NRF2 and may be repurposed for indications within the NRF2 cluster of disease phenotypes. Thus, NRF2 represents one of the first targets fully embraced by classic and systems medicine approaches to facilitate both drug development and drug repurposing by focusing on a set of disease phenotypes that appear to be mechanistically linked. The resulting NRF2 drugome may therefore rapidly advance several surprising clinical options for this subset of chronic diseases., This work was supported by Grants SAF2015-71304-REDT, SAF2016-76520-R, SAF2013-4874R, SAF2015-65267-R, and BIO2014-57518 of the Spanish Ministry of Economy and Competiveness; PII4/00372 from the Health Institute Carlos III; PROMETEOII/2014/071 of Generalitat Valenciana; P_37_732/2016 REDBRAIN of the European Regional Development Fund; Competitiveness Operational Program 2014-2020; and the ERC Advanced Grant RadMed 294683 and COST action 15120 OpenMultiMed (H.H.H.W.S.). M.P. is the recipient of a FPU fellowship of Autonomous University of Madrid. E.G. is supported by a European-cofunded Beatriu de Pinos fellowship. R.L. is supproted by the Miguel Servet II fellow (CPII16/00014)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Reactive oxygen comes of age: Mechanism-based therapy of diabetic end-organ damage

  • Elbatreek, Mahmoud H.
  • Pachado, Mayra P.
  • Cuadrado, Antonio
  • Jandeleit-Dahm, Karin
  • Schmidt, Harald H.H.W.
Reactive oxygen species (ROS) have been mainly viewed as unwanted by-products of cellular metabolism, oxidative stress, a sign of a cellular redox imbalance, and potential disease mechanisms, such as in diabetes mellitus (DM). Antioxidant therapies, however, have failed to provide clinical benefit. This paradox can be explained by recent discoveries that ROS have mainly essential signaling and metabolic functions and evolutionally conserved physiological enzymatic sources. Disease can occur when ROS accumulate in nonphysiological concentrations, locations, or forms. By focusing on disease-relevant sources and targets of ROS, and leaving ROS physiology intact, precise therapeutic interventions are now possible and are entering clinical trials. Their outcomes are likely to profoundly change our concepts of ROS in DM and in medicine in general., H.H.H.W.S. wishes to gratefully acknowledge funding by an ERC Advanced Investigator Grant (294683 – RadMed), an ERC proof-of-concept grant (139-101052 – SAVEBRAIN), and the EU Horizon 2020 programme, REPO-TRIAL. K.J.D. is supported by a fellowship of the National Health and Medical Research Council. A.C. is the recipient of grant SAF2016-76520-R from the Spanish Ministry of Economy and Competitiveness, P_37_732/2016 REDBRAIN from the European Regional Development Fund, and the Competitiveness Operational Program 2014-2020., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

On the clinical pharmacology of reactive oxygen species

  • Casas, Ana I.
  • Nogales, Cristian
  • Mucke, Hermann A. M.
  • Petraina, Alexandra
  • Cuadrado, Antonio
  • Rojo, Ana I.
  • Ghezzi, Pietro
  • Jaquet, Vincent
  • Augsburger, Fiona
  • Dufrasne, Francois
  • Soubhye, Jalal
  • Deshwal, Soni
  • Di Sante, Moises
  • Kaludercic, Nina
  • Di Lisa, Fabio
  • Schmidt, Harald H.H.W.
Rhian M. Touyz, Associate Editor, Reactive oxygen species (ROS) have been correlated with almost every human disease. Yet clinical exploitation of these hypotheses by pharmacological modulation of ROS has been scarce to nonexistent. Are ROS, thus, irrelevant for disease? No. One key misconception in the ROS field has been its consideration as a rather detrimental metabolic by-product of cell metabolism, and thus, any approach eliminating ROS to a certain tolerable level would be beneficial. We now know, instead, that ROS at every concentration, low or high, can serve many essential signaling and metabolic functions. This likely explains why systemic, nonspecific antioxidants have failed in the clinic, often with neutral and sometimes even detrimental outcomes. Recently, drug development has focused, instead, on identifying and selectively modulating ROS enzymatic sources that in a given constellation cause disease while leaving ROS physiologic signaling and metabolic functions intact. As sources, the family of NADPH oxidases stands out as the only enzyme family solely dedicated to ROS formation. Selectively targeting disease-relevant ROS-related proteins is already quite advanced, as evidenced by several phase II/III clinical trials and the first drugs having passed registration. The ROS field is expanding by including target enzymes and maturing to resemble more and more modern, big data–enhanced drug discovery and development, including network pharmacology. By defining a disease based on a distinct mechanism, in this case ROS dysregulation, and not by a symptom or phenotype anymore, ROS pharmacology is leaping forward from a clinical underperformer to a proof of concept within the new era of mechanism-based precision medicine., This study was supported by the European Research Council Advanced Investigator Grant/RadMed [Grant 294683], Proof-of-Concept Grant/SAVEBRAIN [Grant 737586], and H2020 Project REPO-TRIAL [Grant 777111] (to H.H.H.W.S.) and short-term scientific missions by the COST Actions EU-ROS and Open-MultiMed, and Kootstra Talented Fellowship (Maastricht University) (to A.I.C.)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Transcription factor NRF2 as a therapeutic target for chronic diseases: A systems medicine approach

  • Cuadrado, Antonio
  • Manda, Gina
  • Hassan, Ahmed
  • Alcaraz, María José
  • Barbas, Coral
  • Daiber, Andreas
  • Ghezzi, Pietro
  • León, Rafael
  • López, Manuela G.
  • Oliva Miguel, Baldomero
  • Pajares, Marta
  • Rojo, Ana I.
  • Robledinos Antón, Natalia
  • Valverde, Ángela María
  • Guney, Emre
  • Schmidt, Harald H.H.W.
Systems medicine has a mechanism-based rather than a symptom- or organ-based approach to disease and identifies therapeutic targets in a nonhypothesis-driven manner. In this work, we apply this to transcription factor nuclear factor (erythroid-derived 2)-like 2 (NRF2) by cross-validating its position in a protein-protein interaction network (the NRF2 interactome) functionally linked to cytoprotection in low-grade stress, chronic inflammation, metabolic alterations, and reactive oxygen species formation. Multiscale network analysis of these molecular profiles suggests alterations of NRF2 expression and activity as a common mechanism in a subnetwork of diseases (the NRF2 diseasome). This network joins apparently heterogeneous phenotypes such as autoimmune, respiratory, digestive, cardiovascular, metabolic, and neurodegenerative diseases, along with cancer. Importantly, this approach matches and confirms in silico several applications for NRF2-modulating drugs validated in vivo at different phases of clinical development. Pharmacologically, their profile is as diverse as electrophilic dimethyl fumarate, synthetic triterpenoids like bardoxolone methyl and sulforaphane, protein-protein or DNA-protein interaction inhibitors, and even registered drugs such as metformin and statins, which activate NRF2 and may be repurposed for indications within the NRF2 cluster of disease phenotypes. Thus, NRF2 represents one of the first targets fully embraced by classic and systems medicine approaches to facilitate both drug development and drug repurposing by focusing on a set of disease phenotypes that appear to be mechanistically linked. The resulting NRF2 drugome may therefore rapidly advance several surprising clinical options for this subset of chronic diseases., This work was supported by Grants SAF2015-71304-REDT, SAF2016-76520-R, SAF2013-4874R, SAF2015-65267-R, and BIO2014-57518 of the Spanish Ministry of Economy and Competiveness; PII4/00372 from the Health Institute Carlos III; PROMETEOII/2014/071 of Generalitat Valenciana; P_37_732/2016 REDBRAIN of the European Regional Development Fund; Competitiveness Operational Program 2014-2020; and the ERC Advanced Grant RadMed 294683 and COST action 15120 OpenMultiMed (H.H.H.W.S.). M.P. is the recipient of a FPU fellowship of Autonomous University of Madrid. E.G. is supported by a European-cofunded Beatriu de Pinos fellowship. R.L. is supproted by the Miguel Servet II fellow (CPII16/00014).